Vimarsana
Biggest News Aggregation in the World

Eva Pajkrt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eva Pajkrt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eva Pajkrt Today - Breaking & Trending Today

Progesterone protects babies from preterm bir - Vimarsana News

Progesterone protects babies from preterm bir

<p>Women with a short cervix around 20 weeks of pregnancy have an increased risk of preterm birth. Preventing preterm birth in pregnant women with a short cervix is a crucial step in protecting the health of the child. Research from Amsterdam UMC now shows that, in pregnant women with a short cervix around 20 weeks, Progesterone (a hormone) is better than a cervical pessary at reducing the risk of severe preterm birth. This study was published today in the BMJ.</p>

Progesterone more effective than cervical pessary at reducing the risk of severe preterm birth - Vimarsana News

Progesterone more effective than cervical pessary at reducing the risk of severe preterm birth

Women with a short cervix around 20 weeks of pregnancy have an increased risk of preterm birth. Preventing preterm birth in pregnant women with a short cervix is a crucial step in protecting the health of the child.

Cervical pessary versus vaginal progesterone in women with a singleton pregnancy, a short cervix, and no history of spontaneous preterm birth at less than 34 weeks' gestation: open label, multicentre, randomised, controlled trial - Vimarsana News

Cervical pessary versus vaginal progesterone in women with a singleton pregnancy, a short cervix, and no history of spontaneous preterm birth at less than 34 weeks' gestation: open label, multicentre, randomised, controlled trial

Objective To compare the effectiveness of cervical pessary and vaginal progesterone in the prevention of adverse perinatal outcomes and preterm birth in pregnant women of singletons with no prior spontaneous preterm birth at less than 34 weeks’ gestation and who have a short cervix of 35 mm or less. Design Open label, multicentre, randomised, controlled trial. Setting 20 hospitals and five obstetric ultrasound practices in the Netherlands. Participants Women with a healthy singleton pregnancy and an asymptomatic short cervix of 35 mm or less between 18 and 22 weeks’ gestation were eligible...

Source: bmj.com